

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Signature

Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: SUMNER, Calvin Russell Confirmation No.: 9689
Serial No.: 10/568,244 ATTN: Branch Manager
International Application Date: August 25, 2004
For: Treatment Of Learning Disabilities And Motor Skills Disorder With
Norepinephrine Reuptake Inhibitors
Docket No.: X16417

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Attention: Mail Stop Sequence

Sir:

This is in response to the "Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures" dated September 20, 2006, received in connection with the above-identified application, noting the absence of a Sequence Listing.

In response to the above-noted Notification, Applicants have reviewed the specification and failed to find any amino acid or nucleotide sequences for which a Sequence Listing is required.

In order to comply with U.S. P.T.O. regulations, Applicants respectfully request that the Examiner responsible for this application particularly point out where in the present application there are present amino acid or nucleotide sequences, if any, that require submission of a Sequence Listing.

If the Examiner has any questions, or would like to discuss this matter, s/he is invited to contact the undersigned at (317) 433-4983.

Respectfully submitted,

/Charles E. Cohen/
Charles E. Cohen, Ph.D.
Attorney for Applicants
Registration No. 34,565
Phone: 317-433-4983

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

October 20, 2006



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 PO Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U. S. APPLICATION NUMBER NO	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/568,244 ✓	Calvin Russell Sumner ✓	X-16417

25885
 ELI LILLY & COMPANY
 PATENT DIVISION
 P.O. BOX 6288
 INDIANAPOLIS, IN 46206-6288

CEC

RECEIVED

SEP 25 2006

ELI LILLY AND COMPANY
 Patent Division

Response Due 20 Nov 2006

INTERNATIONAL APPLICATION NO.

PCT/US04/25592

I.A. FILING DATE	PRIORITY DATE
08/25/2004 ✓	✓08/27/2003

CONFIRMATION NO. 9689
 371 FORMALITIES LETTER



OC000000020500113

Date Mailed: 09/20/2006

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO	INTERNATIONAL APPLICATION NO.	ATTY DOCKET NO.
10/568,244	PCT/US04/25592	X-16417

FORM PCT/DO/EO/922 (371 Formalities Notice)